Roche more cautious on 2011 on healthcare reforms

February 02, 2011 / 12:14 IST

Roche Holding AG joined peers in striking a cautious note on 2011 as it also grapples with US healthcare reforms and a push in Europe for lower drug prices.

The world's largest maker of cancer drugs, which is looking to cut costs after a string of product setbacks, just fell short of forecasts with a 4% rise in core earnings per share for 2010 as sales growth of top-selling cancer drug Avastin waned.

In local currencies, earnings rose 10%.

first published: Feb 2, 2011 12:08 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347